These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35930662)

  • 1. A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin B.
    Nicolaou KC; Pan S; Shelke Y; Rigol S; Bao R; Das D; Ye Q
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2208938119. PubMed ID: 35930662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Highly Convergent Total Synthesis of Norhalichondrin B.
    Nicolaou KC; Pan S; Shelke Y; Ye Q; Das D; Rigol S
    J Am Chem Soc; 2021 Dec; 143(49):20970-20979. PubMed ID: 34851106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total synthesis of halichondrin A, the missing member in the halichondrin class of natural products.
    Ueda A; Yamamoto A; Kato D; Kishi Y
    J Am Chem Soc; 2014 Apr; 136(13):5171-6. PubMed ID: 24606005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Reverse Approach to the Total Synthesis of Halichondrin B.
    Nicolaou KC; Pan S; Shelke Y; Das D; Ye Q; Lu Y; Sau S; Bao R; Rigol S
    J Am Chem Soc; 2021 Jun; 143(24):9267-9276. PubMed ID: 34105959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrocyclic ketone analogues of halichondrin B.
    Zheng W; Seletsky BM; Palme MH; Lydon PJ; Singer LA; Chase CE; Lemelin CA; Shen Y; Davis H; Tremblay L; Towle MJ; Salvato KA; Wels BF; Aalfs KK; Kishi Y; Littlefield BA; Yu MJ
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5551-4. PubMed ID: 15482922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second generation synthesis of C27-C35 building block of E7389, a synthetic halichondrin analogue.
    Yang YR; Kim DS; Kishi Y
    Org Lett; 2009 Oct; 11(20):4516-9. PubMed ID: 19754145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concise and highly stereoselective synthesis of the C20-C26 building block of halichondrins and Eribulin.
    Shan M; Kishi Y
    Org Lett; 2012 Jan; 14(2):660-3. PubMed ID: 22236198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
    Koczywas M; Frankel PH; Synold TW; Lenz HJ; Mortimer JE; El-Khoueiry AB; Gandara DR; Cristea MC; Chung VM; Lim D; Reckamp KL; Lau DH; Doyle LA; Ruel C; Carroll MI; Newman EM
    Br J Cancer; 2014 Dec; 111(12):2268-74. PubMed ID: 25349975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
    Towle MJ; Salvato KA; Budrow J; Wels BF; Kuznetsov G; Aalfs KK; Welsh S; Zheng W; Seletsky BM; Palme MH; Habgood GJ; Singer LA; Dipietro LV; Wang Y; Chen JJ; Quincy DA; Davis A; Yoshimatsu K; Kishi Y; Yu MJ; Littlefield BA
    Cancer Res; 2001 Feb; 61(3):1013-21. PubMed ID: 11221827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
    Mani S; Swami U
    Drugs Today (Barc); 2010 Sep; 46(9):641-53. PubMed ID: 20967296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Halichondrin B: synthesis of the C(1)-C(15) subunit.
    Burke SD; Jung KW; Lambert WT; Phillips JR; Klovning JJ
    J Org Chem; 2000 Jun; 65(13):4070-87. PubMed ID: 10866625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total synthesis of halichondrin C.
    Yamamoto A; Ueda A; Brémond P; Tiseni PS; Kishi Y
    J Am Chem Soc; 2012 Jan; 134(2):893-6. PubMed ID: 22188422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical stereoselective synthesis of eribulin fragment toward building a hybrid macrocyclic toolbox.
    Jimmidi R; Guduru SK; Arya P
    Org Lett; 2015 Feb; 17(3):468-71. PubMed ID: 25583003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of halichondrin B and eribulin with tubulin.
    Bai R; Nguyen TL; Burnett JC; Atasoylu O; Munro MH; Pettit GR; Smith AB; Gussio R; Hamel E
    J Chem Inf Model; 2011 Jun; 51(6):1393-404. PubMed ID: 21539396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
    Newman S
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1057-66. PubMed ID: 18058576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total syntheses of (+)-vigulariol and (-)-sclerophytin A.
    Crimmins MT; Stauffer CS; Mans MC
    Org Lett; 2011 Sep; 13(18):4890-3. PubMed ID: 21853968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
    Renouf DJ; Tang PA; Major P; Krzyzanowska MK; Dhesy-Thind B; Goffin JR; Hedley D; Wang L; Doyle L; Moore MJ
    Invest New Drugs; 2012 Jun; 30(3):1203-7. PubMed ID: 21526355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
    Dybdal-Hargreaves NF; Risinger AL; Mooberry SL
    Clin Cancer Res; 2015 Jun; 21(11):2445-52. PubMed ID: 25838395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.